-
-
-
-
-
-
-
Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Bristol Myers Squibb Reports Third Quarter 2020 Financial Results
-
-
-
-
-
-
-
Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma
-
-
-
-
-
-
-
Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
-
-
-
-
-
-
-
Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018
-
-
-
-
-
-
-
UPDATE: Exelixis (EXEL) PT Raised to $33 at Needham & Company
-
-
-
-
-
-
-
UPDATE: Stifel Upgrades Exelixis (EXEL) to Buy
-
12,336 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All